English 
-
×
LIPITOR 20 MG 28 TAB
1 × 234.00 EGP
المجموع: 234.00 EGP
ZOCOZET 10 / 10 MG 14 TAB
60.00 EGP
متوفر في المخزون
| * Indications: | ||
| – Primary Hypercholesterolemia: | ||
| & ZOCOZET is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density | ||
| & lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), && non-high-density lipoprotein cholesterol | ||
| & (non-HDL-C), && to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial && | ||
| & non-familial) hypercholesterolemia or mixed hyperlipidemia. | ||
| – Homozygous Familial Hypercholesterolemia (HoFH): ZOCOZET is indicated for the reduction of elevated total-C levels in patients | ||
| & with HoFH. Patients may also receive adjunctive treatments (e.g. LDL apheresis). | ||
| * Dosage && Administration: | ||
| – The patient should be placed on a standard cholesterol-lowering diet before receiving ZOCOZET && should continue on this diet | ||
| & treatment with ZOCOZET. | ||
| – The dosage should be individualized according to the baseline LDL-C level, the recommended goal of therapy, && the patient’s response. | ||
| – ZOCOZET should be taken as a single daily dose in the evening, with or without food. | ||
| – Use in the Elderly: No dosage adjustment is required for elderly patients. | ||
| – Use in Pediatric Patients: Treatment with ZOCOZET is not recommended. | ||
| – Use in Hepatic Impairment: No dosage adjustment is required in patients with hepatic insufficiency. | ||
| & Treatment with ZOCOZET is not recommended in patients with moderate or severe liver dysfunction. | ||
| – Use in Renal Impairment: No dosage adjustment is required in patients with moderate to severe renal insufficiency with ZOCOZET 10/10. | ||
| – Coadministration with other medicines: The safety and effectiveness of ezetimibe administered with fibrates have not been | ||
| & established. Theredore, the combination of ZOCOZET and fibrates should be avoided. | ||
| & There is an increased risk of myopathy when simvastatin is used concomitantly with fibrates (especially gemfibrozil). | ||
| & Therefore, although not recommended, if ZOCOZET is used in combination with gemfibrozil, the dose should not | ||
| & exceed 10/10 mg daily. | ||
| * Contraindications: | ||
| – Hypersensitivity to the active substances or to any of the excipients. | ||
| – Active liver disease or unexplained persistent elevations of serum transaminases. | ||
| – Pregnancy and nursing. | ||
| * Precautions: | ||
| & Myopathy / Rhabdomylosis: | ||
| – Simvastatin, like other inhibitors of HMG-CoA reductase, occasionally causes myopathy, Rhabdomylosis | ||
| & mainfested as muscle pain, tenderness or weakness with creatine kinase (CK) above 10X the upper limit | ||
| & of normal (ULN). | ||
| – The risk of myopathy / rhabdomylosis is increased by concomitant use of ZOCOZET with the following: | ||
& Potent inhibitors of CYP3A4, e.g., itraconazole, ketoconazole, erythromycin, c
كن أول من يقيم “ZOCOZET 10 / 10 MG 14 TAB”يجب عليك تسجيل الدخول لنشر مراجعة. منتجات ذات صلة
أدوية لتنظيم الدهون بالدم
59.00 EGP
أدوية لتنظيم الدهون بالدم
48.00 EGP
أدوية لتنظيم الدهون بالدم
40.00 EGP
|
المراجعات
لا توجد مراجعات بعد.